Literature DB >> 24722173

Testosterone, aging and survival: biomarker or deficiency.

Molly M Shores1, Alvin M Matsumoto.   

Abstract

PURPOSE OF REVIEW: The purpose of this study is to review recent studies that examined the association of endogenous and exogenous testosterone and mortality in older men. RECENT
FINDINGS: Over the past several years, there has been a steep rise in testosterone prescriptions. The increased use of testosterone occurred in the context of several studies that reported an association between low serum testosterone and increased cardiovascular events and mortality. In contrast, recent studies have reported an association between testosterone treatment and adverse events. A testosterone treatment trial of mobility-impaired elderly men with prevalent cardiovascular disease was stopped due to increased cardiovascular events in the T-treated men and a meta-analysis reported increased cardiovascular events in T-treated men. In two recent large observational studies, testosterone treatment was associated with an increased risk for serious adverse cardiovascular events.
SUMMARY: Low testosterone is associated with mortality in multiple cohort studies; however, it is unclear if this is a causal association or due to low testosterone being a biomarker of poor health. Given recent reports of adverse outcomes associated with testosterone treatment, a conservative use of testosterone is warranted in men with cardiovascular disease who may be at greater risk for adverse outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722173      PMCID: PMC4313765          DOI: 10.1097/MED.0000000000000057

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  79 in total

1.  Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria study.

Authors:  Christina Chrysohoou; Demosthenes Panagiotakos; Christos Pitsavos; Gerasimos Siasos; Evangelos Oikonomou; John Varlas; Athanasios Patialiakas; George Lazaros; Theodora Psaltopoulou; Marina Zaromitidou; Polina Kourkouti; Dimitris Tousoulis; Christodoulos Stefanadis
Journal:  Rev Diabet Stud       Date:  2013-05-10

2.  The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).

Authors:  G Hackett; N Cole; M Bhartia; D Kennedy; J Raju; P Wilkinson; A Saghir
Journal:  Int J Clin Pract       Date:  2013-12-20       Impact factor: 2.503

3.  Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.

Authors:  Olga M Calof; Atam B Singh; Martin L Lee; Anne M Kenny; Randall J Urban; Joyce L Tenover; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-11       Impact factor: 6.053

4.  Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients.

Authors:  John Kyriazis; Ioannis Tzanakis; Kostas Stylianou; Irene Katsipi; Demitrios Moisiadis; Antonia Papadaki; Vasiliki Mavroeidi; Stella Kagia; Nikolaos Karkavitsas; Eugene Daphnis
Journal:  Nephrol Dial Transplant       Date:  2011-03-21       Impact factor: 5.992

5.  Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit.

Authors:  Molly M Shores; Victoria M Moceri; David A Gruenewald; Kayla I Brodkin; Alvin M Matsumoto; Daniel R Kivlahan
Journal:  J Am Geriatr Soc       Date:  2004-12       Impact factor: 5.562

6.  Sex steroid hormone concentrations and risk of death in US men.

Authors:  Andy Menke; Eliseo Guallar; Sabine Rohrmann; William G Nelson; Nader Rifai; Norma Kanarek; Manning Feinleib; Erin D Michos; Adrian Dobs; Elizabeth A Platz
Journal:  Am J Epidemiol       Date:  2010-01-18       Impact factor: 4.897

7.  Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study.

Authors:  Robin Haring; Zhaoyang Teng; Vanessa Xanthakis; Andrea Coviello; Lisa Sullivan; Shalender Bhasin; Joanne M Murabito; Henri Wallaschofski; Ramachandran S Vasan
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

Review 8.  Clinical review: Klinefelter syndrome--a clinical update.

Authors:  Kristian A Groth; Anne Skakkebæk; Christian Høst; Claus Højbjerg Gravholt; Anders Bojesen
Journal:  J Clin Endocrinol Metab       Date:  2012-11-01       Impact factor: 5.958

9.  Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction.

Authors:  Giovanni Corona; Matteo Monami; Valentina Boddi; Michela Cameron-Smith; Alessandra D Fisher; Giulia de Vita; Cecilia Melani; Daniela Balzi; Alessandra Sforza; Gianni Forti; Edoardo Mannucci; Mario Maggi
Journal:  J Sex Med       Date:  2010-01-25       Impact factor: 3.802

10.  Sex hormones and cause-specific mortality in the male veterans: the Vietnam Experience Study.

Authors:  A C Phillips; C R Gale; G D Batty
Journal:  QJM       Date:  2011-10-22
View more
  17 in total

1.  Changes in testosterone prescribing patterns after FDA warning.

Authors:  Soum D Lokeshwar; Joshua Bitran; Ranjith Ramasamy
Journal:  Transl Androl Urol       Date:  2019-07

Review 2.  Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases.

Authors:  Arthur P Arnold; Lisa A Cassis; Mansoureh Eghbali; Karen Reue; Kathryn Sandberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-09       Impact factor: 8.311

3.  Aqueous extract of Lespedeza cuneata improves male menopause by increase of nitric oxide and dihydrotestosterone.

Authors:  Yun-Hee Rhee; Sang-Woo Yoo; Seong Lee; Phil-Sang Chung
Journal:  Food Sci Biotechnol       Date:  2018-07-11       Impact factor: 2.391

4.  Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study.

Authors:  Michael A Rosenberg; Molly M Shores; Alvin M Matsumoto; Petra Bůžková; Leslie A Lange; Richard A Kronmal; Susan R Heckbert; Kenneth J Mukamal
Journal:  Clin Cardiol       Date:  2018-06-08       Impact factor: 2.882

Review 5.  Testosterone, myocardial function, and mortality.

Authors:  Vittorio Emanuele Bianchi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

6.  Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study.

Authors:  Do Kyung Kim; Hye Sun Lee; Ju-Young Park; Jong Won Kim; Ji Soo Ha; Jae Heon Kim; Won Jae Yang; Kang Su Cho
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-30       Impact factor: 4.553

Review 7.  Testosterone replacement therapy and voiding dysfunction.

Authors:  Wesley Baas; Tobias S Köhler
Journal:  Transl Androl Urol       Date:  2016-12

8.  Mortality is associated with inflammation, anemia, specific diseases and treatments, and molecular markers.

Authors:  Mark Moeller; Christiane Pink; Nicole Endlich; Karlhans Endlich; Hans-Jörgen Grabe; Henry Völzke; Marcus Dörr; Matthias Nauck; Markus M Lerch; Rüdiger Köhling; Birte Holtfreter; Thomas Kocher; Georg Fuellen
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

9.  Testosterone in advance age: a New Zealand longitudinal cohort study: Life and Living in Advanced Age (Te Puāwaitanga o Ngā Tapuwae Kia Ora Tonu).

Authors:  Martin J Connolly; Ngaire Kerse; Tim Wilkinson; Oliver Menzies; Anna Rolleston; Yih Harng Chong; Joanna B Broad; Simon A Moyes; Santosh Jatrana; Ruth Teh
Journal:  BMJ Open       Date:  2017-11-12       Impact factor: 2.692

10.  The Effect of High-Intensity Interval Training Periods on Morning Serum Testosterone and Cortisol Levels and Physical Fitness in Men Aged 35-40 Years.

Authors:  Tadeusz Ambroży; Łukasz Rydzik; Zbigniew Obmiński; Wiesław Błach; Natalia Serafin; Blanka Błach; Jarosław Jaszczur-Nowicki; Mariusz Ozimek
Journal:  J Clin Med       Date:  2021-05-15       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.